These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 34145693)

  • 21. Clinical use of recombinant factor VIII Fc and recombinant factor IX Fc in patients with haemophilia A and B.
    Wang C; Young G
    Haemophilia; 2018 May; 24(3):414-419. PubMed ID: 29405496
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An Update on Laboratory Diagnostics in Haemophilia A and B.
    Müller J; Miesbach W; Prüller F; Siegemund T; Scholz U; Sachs UJ;
    Hamostaseologie; 2022 Aug; 42(4):248-260. PubMed ID: 35104901
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative analysis of the pivotal studies of extended half-life recombinant FVIII products for treatment of haemophilia A.
    Mannucci PM; Cortesi PA; Di Minno MND; Sanò M; Mantovani LG; Di Minno G
    Haemophilia; 2021 Jul; 27(4):e422-e433. PubMed ID: 33955638
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparison of methods for prediction of pharmacokinetics when switching to extended half-life products in hemophilia A patients.
    Yu JK; Iorio A; Edginton AN
    Thromb Res; 2020 Dec; 196():550-558. PubMed ID: 33157394
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Haemophilia patients' unmet needs and their expectations of the new extended half-life factor concentrates.
    von Mackensen S; Kalnins W; Krucker J; Weiss J; Miesbach W; Albisetti M; Pabinger I; Oldenburg J
    Haemophilia; 2017 Jul; 23(4):566-574. PubMed ID: 28370896
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Application of Multicriteria Decision Analysis to Determine the Value of Prophylaxis Relative to On-Demand Treatment in Hemophilia A and Emicizumab versus Replacement Therapy in the Greek Healthcare Setting.
    Gourzoulidis G; Stefanou G; Economou M; Vakalopoulou S; Filippidis G; Soultatis G; Kontos D; Tzima S; Ntemousis F; Fassa A; Kourlaba G
    Clin Drug Investig; 2022 Jan; 42(1):75-85. PubMed ID: 34874542
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII.
    Hermans C; Mahlangu J; Booth J; Schütz H; Santagostino E; Young G; Lee HY; Steinitz-Trost KN; Blanchette V; Berntorp E
    Haemophilia; 2018 May; 24(3):376-384. PubMed ID: 29732708
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prophylaxis in children with haemophilia in an evolving treatment landscape.
    Mancuso ME; Male C; Kenet G; Kavakli K; Königs C; Blatný J; Fijnvandraat K
    Haemophilia; 2021 Nov; 27(6):889-896. PubMed ID: 34547160
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Perceptions about the efficacy of extended half-life (EHL) factor products in persons with haemophilia (PWH): A national survey of haemophilia providers from haemophilia treatment centres (HTCs) in the United States.
    Swaminathan N; Salinas-Luna V; Acharya S; Sharathkumar A
    Haemophilia; 2021 Nov; 27(6):e780-e783. PubMed ID: 34592042
    [No Abstract]   [Full Text] [Related]  

  • 30. Bleeding outcomes and factor utilization after switching to an extended half-life product for prophylaxis in haemophilia A in Austria.
    Ay C; Feistritzer C; Rettl J; Schuster G; Vavrovsky A; Perschy L; Pabinger I
    Sci Rep; 2021 Jun; 11(1):12967. PubMed ID: 34155229
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predicting Individual Changes in Terminal Half-Life After Switching to Extended Half-Life Concentrates in Patients With Severe Hemophilia.
    Versloot O; Iserman E; Chelle P; Germini F; Edginton AN; Schutgens REG; Iorio A; Fischer K
    Hemasphere; 2022 Apr; 6(4):e694. PubMed ID: 35356797
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Haemophilia care in Europe: a survey of 19 countries.
    O'Mahony B; Noone D; Giangrande PL; Prihodova L
    Haemophilia; 2011 Jan; 17(1):35-40. PubMed ID: 20722746
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-world outcomes with recombinant factor IX Fc fusion protein (rFIXFc) prophylaxis: Longitudinal follow-up in a national adult cohort.
    O'Donovan M; Bergin C; Quinn E; Singleton E; Roche S; Benson J; Bird R; Byrne M; Duggan C; Gilmore R; Ryan K; O'Donnell JS; O'Connell NM
    Haemophilia; 2021 Jul; 27(4):618-625. PubMed ID: 33939224
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factor VIII and IX assays for post-infusion monitoring in hemophilia patients: Guidelines from the French BIMHO group (GFHT).
    Jeanpierre E; Pouplard C; Lasne D; Le Cam Duchez V; Eschwege V; Flaujac C; Galinat H; Harzallah I; Proulle V; Smahi M; Sobas F; Stepina N; Toulon P; Voisin S; Ternisien C; Nougier C;
    Eur J Haematol; 2020 Aug; 105(2):103-115. PubMed ID: 32277501
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.
    Pipe SW; Shima M; Lehle M; Shapiro A; Chebon S; Fukutake K; Key NS; Portron A; Schmitt C; Podolak-Dawidziak M; Selak Bienz N; Hermans C; Campinha-Bacote A; Kiialainen A; Peerlinck K; Levy GG; Jiménez-Yuste V
    Lancet Haematol; 2019 Jun; 6(6):e295-e305. PubMed ID: 31003963
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors.
    Bowyer A; Kitchen S; Maclean R
    Haemophilia; 2020 May; 26(3):536-542. PubMed ID: 32249990
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Kreuth IV: European consensus proposals for treatment of haemophilia with coagulation factor concentrates.
    Giangrande PLF; Peyvandi F; O'Mahony B; Behr-Gross ME; Hilger A; Schramm W; Mannucci PM
    Haemophilia; 2017 May; 23(3):370-375. PubMed ID: 28401658
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimising prophylaxis outcomes and costs in haemophilia patients switching to recombinant FVIII-Fc: a single-centre real-world experience.
    Tagliaferri A; Matichecchia A; Rivolta GF; Riccardi F; Quintavalle G; Benegiamo A; Rossi R; Coppola A
    Blood Transfus; 2020 Sep; 18(5):374-385. PubMed ID: 31855153
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimizing factor prophylaxis for the haemophilia population: where do we stand?
    Blanchette VS; Manco-Johnson M; Santagostino E; Ljung R
    Haemophilia; 2004 Oct; 10 Suppl 4():97-104. PubMed ID: 15479380
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Substitution therapy.
    Shima M; Sidonio RF
    Haemophilia; 2021 Feb; 27 Suppl 3():53-59. PubMed ID: 32558019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.